Additional file 1 of Investigating sources of non-response bias in a population-based seroprevalence study of vaccine-preventable diseases in the Netherlands

Supplementary Material

Additional file 1: of Negative attitude and low intention to vaccinate universally against varicella among public health professionals and parents in the Netherlands: two internet surveys

Overview questionnaire items. (DOCX 18 kb

Sensitivity analysis of the main input in the cost-effectiveness for the 3 strategies.

<p>Sensitivity analysis of the main input in the cost-effectiveness for the 3 strategies.</p

Impact of time horizon on ICER in the scenario with replacement and vaccinating at 65 years of age.

<p>Impact of time horizon on ICER in the scenario with replacement and vaccinating at 65 years of age.</p

The total number cases, deaths and QALYs for IPD and vaccine type CAP and the prevented cases, deaths, QALYS and costs for the different disease end points vaccination, among infants, at age 60 65 and 70, as well as the overall programme costs and the cost-effectiveness results over period of 10 years.

<p>Vaccination coverage 50% for both PCV13 and PPV23 and full coverage for PCV13 among children.</p

Cost-effectiveness plane for the presented scenarios (using a 10 year time horizon).

<p>The dotted line represents a cost-effectiveness threshold of €20,000 per QALY.</p

ICER of the two cohort-approaches under 10-year implementation, using an infinite time horizon.

<p>ICER of the two cohort-approaches under 10-year implementation, using an infinite time horizon.</p

Main inputs for the cost-effectiveness analysis.

<p>Main inputs for the cost-effectiveness analysis.</p

Sensitivity analysis of important assumptions between PCV13 and PPV23 among elderly.

<p>Sensitivity analysis of important assumptions between PCV13 and PPV23 among elderly.</p

Projected cases of invasive pneumococcal disease under the different strategies.

<p>Panel A) current strategy of vaccinating infants with PCV10 including a herd effect for the PCV10 minus PCV7 serotypes and increase of the non-PCV13 serotypes. Panel B) with a strategy when PCV13 is introduced among infants, with a 40% herd protection effect against 19A, also including the indirect effects against PCV10 minus PCV7 serotypes and an increase in non-PCV13 serotypes. Panel C) for a strategy where PCV13 is introduced among infants with a 90% herd protection against 19A, also including the indirect effects against PCV10 minus PCV7 serotypes and an increase in non-PCV13 serotypes.</p